--- source_url: https://hangovr180.com/science/formula/patent-explained.md canonical_url: https://hangovr180.com/science/formula/patent-explained generated_at: 2026-06-28T19:53:17Z build_id: ebfcfef page_type: science-leaf claim_ids: [SF-21, SF-22, SF-02] --- # THE PATENT EXPLAINED *The H180 formula architecture is covered in a patent filed under USPTO conventions, and the language in the patent is deliberately different from the consumer-marketing language on the label because the two are governed by different regulatory frameworks.* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. ## What the Patent Covers The H180 patent covers the formula architecture: the specific combination of DHM at a clinically meaningful dose paired with S-acetyl glutathione and fulvic acid as a delivery vehicle, with the dose ratios that produce the membrane-transport assist for both of the active ingredients. The patent describes the chelation chemistry between fulvic acid and DHM, the bioavailability rescue this provides, and the downstream metabolic and antioxidant effects the combination produces. The supporting biochemistry referenced in the patent draws from the published animal pharmacology on DHM [1] [2] [3]. ## Two Languages, Two Frameworks Patent applications use clinical terminology appropriate for USPTO filings. The consumer marketing language for Hangovr180® follows separate FDA regulations for dietary supplements under DSHEA -- which is why what you read on the label sounds different from what you read in the patent. This is not an inconsistency. It is how the two regulatory frameworks work. (this two-language situation confuses consumers more than it should, and is one of the reasons we wrote out this page in the first place.) The patent uses the technical terms that pharmacology and biochemistry use to describe mechanism. The label uses the bounded structure-function language that DSHEA permits for dietary supplements. > **Claim [SF-21]:** Acts by promoting aldehyde and alcohol metabolism of foods. † > > † These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The consumer-facing claim language is bounded specifically to what published mechanism literature supports, in DSHEA-compliant terms at least. ## Why the Two Languages Differ Under DSHEA, a dietary supplement claim cannot describe disease treatment, cannot describe cure, and cannot extrapolate from preclinical animal mechanism findings into human clinical claims. So the consumer claim "acts by promoting aldehyde and alcohol metabolism of foods" describes a structure-function effect rather than a disease endpoint. The patent text can describe the mechanism using the precise pharmacological terms researchers use without that bounding, because patents are technical documents reviewed by patent examiners, not consumer marketing communications reviewed by FDA. > **Claim [SF-22]:** Triggers the liver to produce more of the aldehyde- and alcohol-metabolizing enzymes (ADH and ALDH) and boosts their efficiency in breaking down aldehydes and alcohols in foods as well as their by-products. † > > † These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The "triggers the liver to produce more" language on the label is the DSHEA-compliant way to describe what the patent describes as enzyme induction. The mechanism is the same. The legal framework that governs how the mechanism gets described is different. ## What the Patent Does Not Cover > **Claim [SF-02]:** Supports overall liver health. † > > † These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The patent does not claim that the formula treats hangover, alcohol use disorder, or any other condition. It claims a specific formula architecture that produces specific biochemical effects, supported by the published mechanism literature on the underlying ingredients. The therapeutic-claim line is exactly where the patent stops, and that boundary is intentional. ## How to Find the Patent The full patent number and filing date will be linked here once the USPTO publication is finalized. For background on the company that holds the patent, see [About Hangovr180®](/about/hangovr180). For the closely related cluster page on the chelation chemistry the patent describes, see [DHM and Fulvic Acid -- The Delivery Mechanism](/science/dhm/dhm-fulvic-synergy). ## Citations 1. [Dihydromyricetin As a Novel Anti-Alcohol Intoxication Medication](https://pmc.ncbi.nlm.nih.gov/articles/PMC3292407/). pmc.ncbi.nlm.nih.gov. 2. [Dihydromyricetin Protects the Liver via Changes in Lipid Metabolism and Enhanced Ethanol Metabolism](https://pmc.ncbi.nlm.nih.gov/articles/PMC7211127/). pmc.ncbi.nlm.nih.gov. 3. [Dihydromyricetin -- A Review on Identification, Biological Activities, Chemical Stability, Metabolism and Bioavailability](https://pmc.ncbi.nlm.nih.gov/articles/PMC7127391/). pmc.ncbi.nlm.nih.gov. ## Read Next - [The Formula -- The Hub](/science/formula) - [The Claims -- The Hub](/science/claims) - [DHM and Fulvic Acid -- The Delivery Mechanism](/science/dhm/dhm-fulvic-synergy) - [About Hangovr180®](/about/hangovr180) **Written by Mark Scott** - Co-Formulator, Hangovr180® | Co-Inventor, [US Application 18/698,010](https://patents.google.com/patent/US20250073201A1) Mark Scott conducted approximately 150 personal formulation tests over six months to develop the H180 ingredient combination. [Editorial standards](/editorial-standards) --- These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Hangovr180® is a dietary supplement. Individual results may vary. Consult your healthcare provider before use if you have any medical conditions or take medications. [US Application 18/698,010](https://patents.google.com/patent/US20250073201A1). Canonical: https://hangovr180.com/science/formula/patent-explained